128 related articles for article (PubMed ID: 19564474)
1. Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes.
Rother KI; Brown RJ; Morales MM; Wright E; Duan Z; Campbell C; Hardin DS; Popovic J; McEvoy RC; Harlan DM; Orlander PR; Brod SA
Diabetes Care; 2009 Jul; 32(7):1250-5. PubMed ID: 19564474
[TBL] [Abstract][Full Text] [Related]
2. C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277: an exploratory study.
Buzzetti R; Cernea S; Petrone A; Capizzi M; Spoletini M; Zampetti S; Guglielmi C; Venditti C; Pozzilli P;
Diabetes; 2011 Nov; 60(11):3067-72. PubMed ID: 21896927
[TBL] [Abstract][Full Text] [Related]
3. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
4. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Walter M; Philotheou A; Bonnici F; Ziegler AG; Jimenez R;
Diabetes Care; 2009 Nov; 32(11):2036-40. PubMed ID: 19690081
[TBL] [Abstract][Full Text] [Related]
5. Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA
Haller MJ; Schatz DA; Skyler JS; Krischer JP; Bundy BN; Miller JL; Atkinson MA; Becker DJ; Baidal D; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Herold KC; Marks JB; Moran A; Rodriguez H; Russell W; Wilson DM; Greenbaum CJ;
Diabetes Care; 2018 Sep; 41(9):1917-1925. PubMed ID: 30012675
[TBL] [Abstract][Full Text] [Related]
6. A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Alpha-1 Antitrypsin (AAT) (Glassia
Lebenthal Y; Brener A; Hershkovitz E; Shehadeh N; Shalitin S; Lewis EC; Elias D; Haim A; Barash G; Loewenthal N; Zuckerman-Levin N; Stein M; Tov N; Rachmiel M
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795482
[TBL] [Abstract][Full Text] [Related]
7. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial.
Forlenza GP; McVean J; Beck RW; Bauza C; Bailey R; Buckingham B; DiMeglio LA; Sherr JL; Clements M; Neyman A; Evans-Molina C; Sims EK; Messer LH; Ekhlaspour L; McDonough R; Van Name M; Rojas D; Beasley S; DuBose S; Kollman C; Moran A;
JAMA; 2023 Mar; 329(12):990-999. PubMed ID: 36826844
[TBL] [Abstract][Full Text] [Related]
8. Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.
Lachin JM; McGee PL; Greenbaum CJ; Palmer J; Pescovitz MD; Gottlieb P; Skyler J;
PLoS One; 2011; 6(11):e26471. PubMed ID: 22102862
[TBL] [Abstract][Full Text] [Related]
9. Antithymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial.
Gitelman SE; Gottlieb PA; Rigby MR; Felner EI; Willi SM; Fisher LK; Moran A; Gottschalk M; Moore WV; Pinckney A; Keyes-Elstein L; Aggarwal S; Phippard D; Sayre PH; Ding L; Bluestone JA; Ehlers MR;
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):306-16. PubMed ID: 24622416
[TBL] [Abstract][Full Text] [Related]
10. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial.
Raz I; Avron A; Tamir M; Metzger M; Symer L; Eldor R; Cohen IR; Elias D
Diabetes Metab Res Rev; 2007 May; 23(4):292-8. PubMed ID: 17124720
[TBL] [Abstract][Full Text] [Related]
11. Proinsulin to C-Peptide Ratio in the First Year After Diagnosis of Type 1 Diabetes.
Freese J; Al-Rawi R; Choat H; Martin A; Lunsford A; Tse H; Mick G; McCormick K
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4318-e4326. PubMed ID: 34228132
[TBL] [Abstract][Full Text] [Related]
12. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Orban T; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Marks JB; Monzavi R; Moran A; Raskin P; Rodriguez H; Russell WE; Schatz D; Wherrett D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9789):412-9. PubMed ID: 21719096
[TBL] [Abstract][Full Text] [Related]
13. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes.
Walter M; Kaupper T; Adler K; Foersch J; Bonifacio E; Ziegler AG
Diabetes Care; 2010 Jul; 33(7):1443-8. PubMed ID: 20357369
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial.
von Herrath M; Bain SC; Bode B; Clausen JO; Coppieters K; Gaysina L; Gumprecht J; Hansen TK; Mathieu C; Morales C; Mosenzon O; Segel S; Tsoukas G; Pieber TR;
Lancet Diabetes Endocrinol; 2021 Apr; 9(4):212-224. PubMed ID: 33662334
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group.
Skyler JS; Rabinovitch A
J Diabetes Complications; 1992; 6(2):77-88. PubMed ID: 1611143
[TBL] [Abstract][Full Text] [Related]
16. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes.
Ataie-Jafari A; Loke SC; Rahmat AB; Larijani B; Abbasi F; Leow MK; Yassin Z
Clin Nutr; 2013 Dec; 32(6):911-7. PubMed ID: 23395257
[TBL] [Abstract][Full Text] [Related]
17. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Mastrandrea L; Yu J; Behrens T; Buchlis J; Albini C; Fourtner S; Quattrin T
Diabetes Care; 2009 Jul; 32(7):1244-9. PubMed ID: 19366957
[TBL] [Abstract][Full Text] [Related]
18. Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes.
Brod SA; Atkinson M; Lavis VR; Brosnan PG; Hardin DS; Orlander PR; Nguyen M; Riley WJ
J Interferon Cytokine Res; 2001 Dec; 21(12):1021-30. PubMed ID: 11798459
[TBL] [Abstract][Full Text] [Related]
19. A randomised, single-blind, placebo-controlled, dose-finding safety and tolerability study of the anti-CD3 monoclonal antibody otelixizumab in new-onset type 1 diabetes.
Keymeulen B; van Maurik A; Inman D; Oliveira J; McLaughlin R; Gittelman RM; Roep BO; Gillard P; Hilbrands R; Gorus F; Mathieu C; Van de Velde U; Wisniacki N; Napolitano A
Diabetologia; 2021 Feb; 64(2):313-324. PubMed ID: 33145642
[TBL] [Abstract][Full Text] [Related]
20. Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA
Haller MJ; Long SA; Blanchfield JL; Schatz DA; Skyler JS; Krischer JP; Bundy BN; Geyer SM; Warnock MV; Miller JL; Atkinson MA; Becker DJ; Baidal DA; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Herold KC; Marks JB; Moran A; Rodriguez H; Russell WE; Wilson DM; Greenbaum CJ;
Diabetes; 2019 Jun; 68(6):1267-1276. PubMed ID: 30967424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
